What is the role of sunitinib (Sutent) in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Sunitinib (Sutent) is a multikinase inhibitor approved by the FDA for the treatment of metastatic kidney cancer that has progressed after a trial of immunotherapy. The receptor tyrosine kinases inhibited by sunitinib include vascular endothelial growth factor receptors 1,2, and 3 (VEGFR 1-3), platelet-derived growth factor receptor alpha (PDGFR-alpha), and PDGFR-beta. Approval of sunitinib was based on the high response rate (40% partial responses), a median time to progression of 8.7 months, and an overall survival of 16.4 months. [28]

The recommended dose of sunitinib for advanced RCC is one 50 mg oral dose taken once daily, with or without food, on a schedule of 4 weeks on treatment, followed by 2 weeks off treatment. [29]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!